Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference

Rhea-AI Summary

Theseus Pharmaceuticals (NASDAQ: THRX) will participate in the 12th Annual Jefferies London Healthcare Conference from November 16-19, 2021. Tim Clackson, Ph.D., President and CEO, will host a virtual fireside chat, with a pre-record available starting November 18 at 8:00am GMT. This event will showcase Theseus' focus on targeted therapies for cancer treatment, including the lead candidate, THE-630, for advanced gastrointestinal stromal tumors. Archived webcasts will be accessible on the Jefferies website for 30 days after the event.

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference, taking place November 16-19, 2021.

Presentation Details:
Event: Jefferies London Healthcare Conference
Date / Time: Pre-record available beginning Thursday, November 18^th at 8:00am GMT / 3:00am ET and available through Friday, November 19^th at 5:00pm GMT / 12:00pm ET
Format: Fireside Chat

A webcast link from the Jefferies fireside chat will be accessible under "Events" in the "Investors & Media" section of the Company's website at www.theseusrx.com. Following the event, archived webcasts will also be available on the Jefferies website for 30 days.

About Theseus Pharmaceuticals, Inc.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com

Investor Contact
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-virtually-in-jefferies-london-healthcare-conference-301420559.html

SOURCE Theseus Pharmaceuticals

FAQ

What is the date of the Jefferies London Healthcare Conference for THRX?

The Jefferies London Healthcare Conference will take place from November 16-19, 2021.

Who is presenting on behalf of Theseus Pharmaceuticals at the conference?

Tim Clackson, Ph.D., President and CEO, will present at the conference.

When will the fireside chat for THRX be available?

The fireside chat will be available starting November 18, 2021, at 8:00am GMT.

What is THE-630, the lead candidate of THRX?

THE-630 is a pan-variant KIT inhibitor for treating advanced gastrointestinal stromal tumors (GIST).

Where can I find the webcast of the THRX event?

The webcast link will be available in the 'Events' section of the Theseus Pharmaceuticals website.